Abstract
Ubiquitin-conjugating enzyme E2C (UBE2C) has been found to participate in the process of several cancers. However, the role of UBE2C in prostate cancer has not been reported. To investigate the function of UBE2C in prostate cancer, several methods were used. UBE2C promoted the proliferation and viability of prostate cancer cells through MTT and colony formation assay and increased the number of invaded or migrated cells in Matrigel or Transwell assay based on its function of inducing EMT. UBE2C also promoted tumor formation in vivo. Our results suggest that UBE2C acts as an oncogene in prostate cancer progression and may be a candidate marker of diagnosis for this disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.